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Particularities of Hepatic 
Sarcoidosis
Laura Iliescu and Letitia Toma
Abstract
Liver sarcoidosis is usually an underdiagnosed disease, which can have severe 
implications in the evolution of a patient. Due to the fact that sarcoidosis is a disease 
based on immunological disorders, it is only natural that the liver should be one of 
the first organs to be affected. The imaging of liver sarcoidosis is of marked impor-
tance, especially in the differential diagnosis of the disease. While the histology 
aspect of sarcoidosis is relatively clear and should prompt a positive diagnosis, 
finding a liver granuloma in ultrasonography raises a multitude of questions and 
implies extensive testing for diagnosis. Furthermore, treatment of liver sarcoidosis 
is controversial, taking into account the possibility of developing end-stage liver 
disease in patients with a long history of sarcoidosis. This chapter aims to review 
diagnostic and treatment options for liver sarcoidosis and to determine the best 
management of these patients.
Keywords: liver granuloma, sarcoidosis, cholestasis, abdominal ultrasonography, 
liver transplant
1. Introduction
Liver granulomas may appear as either a primary condition or secondary to 
systemic disease [1]. They consist of modified macrophages and other inflam-
matory cells that adhere due to antigenic stimulation. If there is liver inflamma-
tion within or surrounding these granulomas, the term used is granulomatous 
hepatitis.
The prevalence of liver granulomas is as high as 15% in biopsy specimens in 
the general population [2], with a higher frequency (up to 75%) in special popula-
tions like HIV-infected patients and patients with prolonged fever of unknown 
etiology [3].
Common causes of liver granulomas include primary biliary cirrhosis, sar-
coidosis, infectious diseases (Mycobacterium tuberculosis, Listeria, Histoplasma, 
Schistosoma and hepatitis C virus), drugs and malignancies [1]. However, up to 
36% of all liver granulomas are of unknown etiology [4].
Granuloma formation takes place during a chronic inflammation reaction, 
involving epithelioid cells, lymphocytes, monocytes and plasma cells, recruited 
under the influence of T-cell interleukins [1]. The reaction is consistent with a 
delayed hypersensitivity cellular immune response to pathogenic material.
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2. Etiology and histology of hepatic sarcoidosis
Sarcoidosis is a non-caseating granulomatous disease, of unknown etiology, 
affecting primarily mediastinum lymph nodes and the lungs. Its diagnosis is mainly 
an exclusion one, requiring elimination of all infectious and antigen-producing 
diseases [5]. The pathognomonic histological aspect is of non-caseating granulomas 
containing epithelioid cells [6]. Typically, sarcoidosis affects the lungs in over 
90% of the cases, but several other organs may be involved, including the liver, the 
skin, the central nervous system, the heart and the eyes [7, 8]. The main peak of 
incidence is described for the age group 20–39 years for both genders, with women 
having a second incidence peak at the ages of 65–69 [9].
The main pathophysiological process in sarcoidosis is the immune paradox, 
with exaggerated inflammation at disease sites and relative anergy in the unaf-
fected regions [10]. Several theories have been suggested as explanation for this 
paradox [11]. First, there may be an imbalance between regulatory and effector 
T-cell lymphocytes that accumulate in the periphery of the granuloma and exert 
inhibiting effects on naïve T cells. Second, the intense immune stimulation at the 
disease sites causes lymphocytes to converge in these sites and produces a relative 
peripheral leukopenia. Third, subsequent to disease chronicity, immunosuppres-
sive T cells are more abundant in the peripheral blood, producing anergy to other 
antigen stimulations.
The result of this immune imbalance is the non-caseous granuloma, probably 
containing a partially degraded antigen surrounded by macrophages and T-helper 
cells. [11]. These macrophages will in turn differentiate into epithelioid cells that 
will eventually fuse to form multinucleate giant cells. The periphery of the granu-
loma contains CD8+ T cells, regulatory T cells, fibroblasts and B cells.
As mentioned before, a large percentage of patients with sarcoidosis present 
with typical signs of the disease in liver biopsy specimens, while only 10–30% have 
abnormal liver tests [12]. Risk factors associated with liver involvement in sarcoid-
osis include African-American ethnicity, exposure to pegylated interferon and 
splenomegaly [13].
The histology aspect of liver sarcoidosis is defined by the presence of epithe-
lioid granulomas in both the portal tracts and hepatic lobules [14]. About 30% of 
patients with liver sarcoidosis have histological chances similar to those in primary 
biliary cirrhosis or primary sclerosing cholangitis [15]. However, typical granulo-
mas in sarcoidosis are larger, better defined and associated with multinucleate giant 
cells. Occasionally, the granulomas may conflate resulting in large masses, which 
can be misdiagnosed for liver tumors on abdominal imaging [15]. Furthermore, 
granulomas from primary biliary cirrhosis are portal based and are associated with 
bile duct destruction, unlike sarcoidosis. In sarcoidosis, there are other signs of 
organ involvement, as it is a systemic disease, and anti-mitochondrial antibodies 
are always negative. The histological differential diagnosis between liver sarcoidosis 
and drug-induced liver injury (DILI) takes into account the fact that DILI manifests 
as granulomatous hepatitis, with small intralobular granulomas with periportal 
inflammation [16].
The most important aspect of differentiation between sarcoidosis and infectious 
granulomas is the presence of caseous necrosis, typical for infectious granulomas 
[17]. As such, caseating granulomas with central necrosis must be considered infec-
tions, until serious evidence eliminates the diagnosis. However, histochemical stains 
have a low sensitivity for infections, and false-negative results are frequent.
The histology aspect of sarcoidosis may vary, thus explaining the differences 
in symptomatology and evolution [15]. In a report of 100 cases with sarcoidosis 
and liver biopsy due to abnormal liver test results, all patients presented with liver 
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granulomas, 99% non-caseating, frequently located in the periportal region. None 
of the patients had serology or cultures suggestive for infectious granulomas. Three 
types of histologic alterations were encountered: most patients had cholestatic 
changes (58%), while 41% presented with necroinflammatory changes and 20% 
presented with vascular alterations. Patients with cholestasis presented with histol-
ogy aspects similar to those encountered in primary biliary cirrhosis (19 patients 
with bile duct lesions) or primary sclerosing cholangitis (13 patients with periductal 
fibrosis). Biliary ductopenia was noted in 37 out of 58 patients with cholestasis. 
Twelve patients presented with acute cholangitis without signs of biliary obstruc-
tion. Necroinflammatory changes consisted of spotty necrosis and chronic portal 
inflammation, suggesting hepatitis of various etiologies (viral or drug-induced). 
Vascular alterations encountered in these patients were sinusoidal dilatation and 
nodular regenerative hyperplasia. Fibrosis was present in 21 patients overall: 13 
patients with periportal fibrosis, 2 patients with bridging fibrosis and 6 patients 
with cirrhosis.
3. Clinical aspects of hepatic sarcoidosis
The spectrum of liver damage in sarcoidosis varies greatly from asymptomatic 
patients to end-stage liver disease [12]. Commonly, mild liver cytolysis can be 
observed (in about 30% of patients with positive biopsies for sarcoidosis) [12]. 
Abdominal imaging reveals hepatomegaly in less than 50% of the cases [18].
Non-specific symptoms are frequently encountered in patients with sarcoidosis, 
including malaise, fatigue, arthralgias and fever [19]. Symptoms suggesting liver 
involvement are jaundice, pruritus and abdominal pain in the upper right quadrant, 
due to chronic cholestasis and distension of the Glisson capsule by hepatomegaly 
containing granulomas [19, 20]. One report even describes fever and arthral-
gias in 70% of patients with liver sarcoidosis, as opposed to those without liver 
 involvement [21].
Rarely, the chronic evolution of liver sarcoidosis can lead to portal hypertension 
and in a minority of cases, end-stage liver disease with the need for liver trans-
plantation [19]. Also, few cases of association between liver sarcoidosis and Budd-
Chiari syndrome have been reported [22]. In a report published in 2006 [23], out 
of 180 patients, 50% had altered liver function associated with sarcoidosis, while 
13% of the patients had liver affection without lung sarcoidosis. Fourteen patients 
presented with liver cirrhosis from the diagnosis of liver involvement, while two 
patients developed cirrhosis in the course of the disease, despite corticoid therapy. 
Six patients underwent liver transplantation, and recurrence of liver sarcoidosis was 
reported in one patient after transplantation.
Case reports of liver sarcoidosis show either non-specific general symptomatol-
ogy or altered liver enzymes at the time of diagnosis. For example, liver sarcoidosis 
was diagnosed in a 41-year-old patient with a known history of ocular and lung 
sarcoidosis for 6 years, who presented with an increase in liver enzymes during 
periodic follow-up [24]. Final diagnosis was based on positron emission tomogra-
phy and subsequent liver biopsy.
Liver sarcoidosis may also appear in association with cutaneous sarcoidosis. In a 
report of 40 cases of patients with cutaneous sarcoidosis (with positive histology) 
monitored for a mean period of 9 years, 32 patients developed lung and thoracic 
lymph node disease; 1 patient developed liver sarcoidosis [25].
A recent case series of 7 patients with liver sarcoidosis found that the liver was 
affected in the evolution of known sarcoidosis in 2 cases, while the other 5 had liver 
involvement at the time of diagnosis [26]. Four patients presented with upper right 
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quadrant abdominal pain and one patient had incidentally discovered altered liver 
enzymes on routine evaluation. One patient also presented with cutaneous sarcoid-
osis (erythematous lesions on the scalp), one patient had ocular involvement (Sicca 
syndrome), while one patient had both skin and ocular manifestations (uveitis 
and sarcoid nodules). Notably, hepatomegaly was observed in all 7 patients, with 
2 patients presenting with concomitant splenomegaly. One of these patients was 
found to have primary Budd-Chiari syndrome.
Another case report presents the diagnosis of liver sarcoidosis in an asymptom-
atic 66-year-old woman with abnormal liver function test on routine evaluation 
[27], requiring extensive evaluation by tomography and magnetic resonance imag-
ing and ultimately liver biopsy for diagnostic confirmation.
In rare instances, necrosis of the sarcoid granulomas may appear [28]. The case 
of a 37-year-old woman with sudden onset of fever and right abdominal pain is 
reported. Initially, the patient was treated for suspicion of intra-abdominal infec-
tion. The presence of liver and splenic lesions on abdominal CT scan prompted the 
need for liver biopsy, showing necrotizing granulomas negative for infection, with 
remission of symptoms after corticoid therapy.
Few cases of typical sarcoidosis have been described under the age of 20 years 
[29]. One case report [30] presents the diagnosis of pediatric-onset adult sarcoid-
osis, with lung, liver and lymph nodes involvement. The 9-year-old patient pre-
sented with asthenia, weight loss, hepatosplenomegaly and 2 palpable lymph nodes 
(supraclavicular and inguinal). The major aspect of this case is the emphasis on the 
differential diagnosis from lymphoproliferative diseases in patients with abdominal 
organomegaly.
Furthermore, liver sarcoidosis may evolve silently with the development 
of cirrhosis and portal hypertension. Such a case was reported in 2012 [31] in 
a 48-year-old patient, complaining of abdominal pain. CT scan in this patient 
revealed hepatosplenomegaly and increased diameter of portal and splenic vein, 
suggestive of portal hypertension. In the absence of autoimmune and viral markers, 
the patient underwent liver biopsy with a positive diagnosis of liver sarcoidosis. 
Repeated thorax CT scans did not reveal pulmonary or lymph nodes involvement. 
Splenectomy was required due to severe pancytopenia. The patient’s evolution 
was complicated with the development of ascites; the authors note the absence of 
esophageal or gastric varices as a sign of portal hypertension in this patient.
A review of 37 patients with sarcoidosis and portal hypertension [20] found a 
predominance of female patients. All patients presented with hepatosplenomegaly 
and esophageal varices in different degrees. Direct measurement of pressure in 
the portal vein was performed in 18 patients, with an average portal pressure of 
24.6 mmHg. The authors emphasize the different physiopathological aspects of 
portal hypertension in sarcoidosis: healing fibrosis, large sarcoid granulomas and 
small perigranular arteriovenous shunts may increase sinusoidal resistance leading 
to portal hypertension. A presinusoidal blockage may occur by the direct pres-
sure of the sarcoid granulomas in the portal areas. Another possible explanation is 
ischemia-induced fibrosis and cirrhosis in the setting of primary granulomatous 
phlebitis of the portal and hepatic veins [32].
Liver sarcoidosis can be associated with chronic cholestasis, either intrahepatic 
(mimicking primary biliary cirrhosis or primary sclerosing cholangitis) or extrahe-
patic (by hilar or ductal compression by adenopathies) [20]. Clinical manifestations 
of intrahepatic cholestasis reported in 31 patients were pruritus, jaundice and right 
quadrant abdominal pain. Extrahepatic cholestasis is far rarer [33], and CT scan and 
endoscopic retrograde cholangiopancreatography are required for the diagnosis.
Acute sarcoidosis rarely presents with liver involvement [20]. Usually, the 
clinical presentation is dominated by pulmonary symptoms (cough, dyspnea and 
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chest discomfort) and constitutional symptoms (fever, fatigue, malaise and weight 
loss). Liver involvement may be suspected in the presence of jaundice, pruritus or 
abnormal liver function tests.
Figure 1 summarizes possible clinical aspects of liver sarcoidosis.
4. Laboratory findings in liver sarcoidosis
Both cholestasis and hepatocytolysis can appear in liver sarcoidosis. Abnormal 
liver tests are found in up to 40% of patients with sarcoidosis, with a predominance 
of cholestasis (increased alkaline phosphatase (ALP), gamma-glutamyl transpep-
tidase (γGT) and minor increases in bilirubin levels) [34]. ALP can be increased 
in up to 90% of the patients with symptoms of hepatic disease, up to 10 times the 
upper normal limit [19]; by contrast, increases in transaminases are mild and less 
frequent. The severity of the cholestasis is associated with the degree of granuloma-
tous inflammation [35].
Peripheral lymphopenia, especially noted in CD4+ positive cells, can be useful 
in suspecting sarcoidosis [31]. Hypercalcemia and hypercalciuria can also be found, 
but unrelated to liver involvement.
In cases with portal hypertension, frequent findings are pancytopenia [20, 
31] with the predominance of thrombocytopenia. Hypoalbuminemia can also be 
encountered as a sign of liver disease.
Most laboratory determinations are aimed at excluding other causes of liver 
disease. Most commonly used are viral serology markers for hepatitis B and C infec-
tion, serum markers for Wilson’s disease and hemochromatosis (especially in young 
patients), autoantibody determinations for celiac disease, primary biliary cirrhosis 
and autoimmune hepatitis. Table 1 summarizes the main serum determinations to 
exclude other etiologies of liver disease [36].
Patients with active disease may present with increased levels of serum inflam-
mation markers (such as erythrocyte sedimentation rate and C-reactive protein), 
regardless of the organs involved [37]. CRP may also be associated with fatigue in 
sarcoidosis. However, these tests are not specific in any way to sarcoidosis.
There are yet no serum markers for the clear diagnosis of sarcoidosis. High 
serum levels of angiotensin-converting enzyme have been associated with sarcoid-
osis and are present in about 60% of patients with active disease [19]. Nevertheless, 
the test is far from pathognomonic, with low positive and negative predicting values 
Figure 1. 
Summary of clinical aspects encountered in liver sarcoidosis.
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(84% and 74%, respectively). Normal ACE levels should not be used for exclusion 
of sarcoidosis-they can be encountered in patients with chronic disease or patients 
under corticoid therapy. High values are indicative of sarcoidosis and can be used 
in excluding other granulomatous diseases. However, inflammatory bowel disease 
can also manifest with high level of ACE, and the differential diagnosis is difficult, 
especially when primary biliary cirrhosis is associated. Increased levels of ACE can 
also be found in pulmonary silicosis, asbestosis, military tuberculosis, diabetes 
mellitus and hyperthyroidism [38].
5. Imaging in liver sarcoidosis
In asymptomatic patients, a routine laboratory testing or abdominal ultrasound 
can raise suspicion of liver disease, especially in the setting of a known history of 
sarcoidosis. In fact, some authors recommend routine testing for liver sarcoidosis in 
the course of the disease [19].
Abdominal ultrasonography frequently reveals hepatomegaly, possibly associ-
ated with splenomegaly in the case of splenic involvement or portal hypertension. 
One review found that 8% of patients with liver sarcoidosis had marked hepato-
megaly, with an anteroposterior diameter of over 25 cm [39]. The general aspect of 
Determination Result Diagnosis Comments
HBs antigen Positive Hepatitis B infection Determine HBV-DNA
Search for HDV 
co-infection
HCV antibodies Positive Possible hepatitis C infection Confirm infection with 
HCV- RNA
IgM antibodies for 
cytomegalovirus
Positive Possible CMV hepatitis Determine viremia
Ceruloplasmin Low values Possible Wilson’s disease Confirm with genetic 
testing
Serum copper High values
Urinary copper High values
Serum ferritin High values Possible hemochromatosis Confirm with genetic 
testing/liver biopsy
Transferrin levels High values
Antinuclear antibodies Positive Possible autoimmune hepatitis Search for concurrent 
abnormal tests and/or 
other organ involved
Antismooth muscle 
antibodies (SMA)
Positive Possible autoimmune hepatitis
Antiliver kidney muscle 
antibodies (LKM-1)
Positive Possible autoimmune hepatitis
Antimitochondrial 
antibodies
Positive Possible primary biliary 
cirrhosis
Antineutrophil 
cytoplasmic antibodies
Positive Possible Wegener’s disease, 
other vasculitis
Anti-Saccharomyces 
cerevisiae
Positive Possible inflammatory bowel 
disease, associated with 
primary biliary cirrhosis
Antitissue 
transglutaminase
Positive Possible celiac disease
Table 1. 
Biological parameters required in the etiology of liver disease (adapted from [36]).
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the liver is of increased echogenicity, either homogenous or diffusely heterogeneous 
[40] (Figure 2). The aspect sometimes may resemble fatty liver disease [41].
Focal liver nodules may appear on ultrasonography in the case when sarcoid 
granulomas conflate and form macroscopic masses. Such nodules have been 
described in up to 19% of patients [40]. Typically, there are innumerous round 
nodules, diffusely distributed, with size ranging from 1 to 2 mm to centimeters [39]. 
Color Doppler ultrasonography reveals hypovascularization of the nodules.
Splenomegaly is also reported in almost 60% of patients with liver sarcoidosis 
[40], with markedly increased dimensions (over 18 cm) in 6% of the cases. In 15% 
of cases, splenomegaly is associated with hypoechoic splenic nodules. The fre-
quency of nodules appears to vary according to geographical distribution and ethnic 
characteristics [40]. They are distributed diffusely within the splenic parenchyma, 
with a medium size of 1 cm [42]; they demonstrate hypovascularization on Doppler 
analysis. Isolated splenic nodules are more frequent than isolated hepatomegaly or 
liver nodules in sarcoidosis.
Up to 76% of patients with liver and splenic nodules also associate with enlarged 
abdominal lymph nodes [43], with infrequent punctate calcifications. Adenopathies 
are usually found periportal, celiac, paracaval and para-aortic, with dimensions 
ranging from 1 cm to 4–6 cm [44, 45]. Larger perihepatic lymph nodes can be asso-
ciated with advanced liver disease. They raise the need for differential diagnosis to 
malignant conditions (primarily lymphoproliferative disorders), intra-abdominal 
infections and benign conditions such as primary biliary cirrhosis or chronic 
hepatitis C.
Contrast-enhanced ultrasonography (CEUS) has emerged as a new, reliable and 
non-invasive means of evaluation of liver disease [45]. CEUS has proven its greatest 
utility in differentiating between benign and malignant liver and splenic nodules, 
with sensitivity and specificity similar to those of CT scans. The use of CEUS in 
abdominal sarcoidosis has been evaluated in small case series or case reports [45], 
due to the scarcity of the cases and also to the fact that patients with hepatosplenic 
sarcoidosis rarely present with focal lesions, making them difficult candidates for 
CEUS (Figure 3).
If hypoechoic liver lesions appear on conventional ultrasonography, they have 
variable arterial enhancement with progressive washout in the portal and late 
phases [45].
Figure 2. 
Abdominal ultrasonography revealing diffusely heterogeneous hepatomegaly in a patient with liver sarcoidosis.
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Regarding hypoechoic splenic nodules, on CEUS, they appear as progressive 
hypoenhancing nodules in the arterial and parenchymal phases. As the investiga-
tion progresses into the parenchymal phase, the lesion-to-parenchyma contrast dif-
fusion is increased. The mild enhancement in the arterial phase can be homogenous 
or diffusely heterogeneous, while in the parenchymal phase, it may be homogenous 
or with a dotted pattern. Sometimes, peripheral blood vessels may be visible and 
have an irregular aspect. These characteristics may be compatible with malignant 
conditions; therefore, biopsy is mandatory for a clear diagnosis.
A study performed in 2013 evaluated the efficacy of CEUS in diagnostic abdominal 
disease in 21 patients with pulmonary sarcoidosis [46]. Eighteen patients had no hepa-
tosplenic disease, one patient had splenic nodules and two patients had liver lesions. 
CEUS as well as CT scan and abdominal MRI gave concordant results. The authors 
underline the importance of CEUS in the evaluation of these patients, as it offers the 
same information without any contraindications that CT or MRI might have including 
allergy to contrast, contrast-induced nephropathy or the presence of pacemakers or 
metallic devices. It is also suggested that CEUS should be used in the first evaluation of 
patients with pulmonary sarcoidosis and in their monitorization during treatment.
The latest review on the importance of CEUS in the evaluation of abdominal 
involvement in sarcoidosis describes the following characteristics [47]:
• Liver aspect on CEUS: variable nodular enhancement in the arterial phase, 
progressive hypoenhancement in the portal and late phases.
• Splenic aspect on CEUS: progressive hypoenhancement in the arterial and 
parenchymal phase. Possible patterns: rim-like, homogenous, dotted.
Endoscopic ultrasound elastography could also be used to characterize liver 
sarcoidosis [47]. The lesions may appear as single masses with blue hard patterns 
within and around.
However, the lack of sufficient data especially from clinical trials or large studies 
makes it impossible to establish clear recommendations on the use of CEUS in liver 
sarcoidosis; therefore, other imagistic methods are required for a complete positive 
diagnosis.
CT scans in liver sarcoidosis may reveal homogenous hepatomegaly (with 
possible low-density intrahepatic septa) [40] (Figure 4). Liver nodules appear as 
hypoenhanced masses as opposed to the adjacent normal liver parenchyma. There is 
Figure 3. 
CEUS in a patient with liver sarcoidosis—diffuse disease, without focal lesions (late phase).
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no visible peripheral enhancement. Typically, the nodules have no mass effect. 
Sometimes, these numerous hypodense nodules with variable dimensions warrant 
differential diagnosis to metastatic disease of the liver, but also miliary liver tuber-
culosis, fungal infections or Langerhans cell histiocytosis [48].
CT scan is useful in the diagnosis of liver cirrhosis and portal hypertension sub-
sequent to sarcoidosis [49], as rare as they appear. Typical aspects include hyper-
trophy of the caudate lobe, dilatation of the portal and splenic veins, irregular liver 
contour, collateral circulation vessels around the digestive tract as well as ascites.
MRI evaluation of liver sarcoidosis may reveal hypointense and hypoenhancing 
nodules relative to the adjacent liver parenchyma [40] (Figures 5 and 6). Still, the 
particularity of the imaging is the lack of mass effect or any impact of the nodules 
on the surrounding parenchyma or adjacent vessels.
T2-weighted fat-saturated images are the most conclusive in diagnosing hypoin-
tense nodules in liver sarcoidosis. This is an important part in the differential diag-
nosis from malignancies, as these appear most frequently as hyperintense. Other 
signs suggestive of sarcoidosis are irregular contour of the liver and high periportal 
Figure 4. 
Abdominal CT scan of a patient with liver sarcoidosis showing homogeneous hepatomegaly and splenomegaly.
Figure 5. 
MRI of a patient with diffuse liver sarcoidosis.
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signal intensity [50]. However, cases have been described where masses with T2 
hyperintensity have proven to be liver sarcoidosis in histology examination [51].
Nodules located in the hilar area need to be differentiated from cholangiocarcino-
mas. In cases thus located or in the case of hilum adenopathies and subsequent ste-
nosis of biliary ducts, magnetic resonance cholangiopancreatography may reveal the 
stenosis with dilatation of intrahepatic bile ducts, similar to that in a Klatskin tumor 
[52]. In this case, the positive diagnosis is set by biopsy, usually obtained by ERCP.
6. Management of liver sarcoidosis
Guidelines for the management of sarcoidosis are relatively old and have little 
approach to the possibility of liver sarcoidosis [53]. Staging of sarcoidosis takes into 
account the pulmonary and mediastinal lymph node involvement, without consid-
ering systemic disease. Recommendations for monitoring are as follows:
• Surveillance for 2 years to determine the need for systemic therapy (taking into 
account the fact that many patients present spontaneous remission).
• Therapy should be initiated in patients with severe, active or progressive disease.
• Patients with remission after corticoid therapy should be more closely moni-
tored as the relapse rate is higher than in patients with spontaneous remission.
Mild disease (including skin lesions, uveitis and respiratory symptoms) may 
be managed with topical steroids. Systemic or progressive disease can be managed 
with systemic corticotherapy, and if necessary cytotoxic therapy or antimalaric 
agents. Cardiac or neurologic involvement, hypercalcemia and ocular disease not 
responsive to topic therapy are clear indications for systemic therapy. Regarding 
pulmonary disease, the consensus is that progressive pulmonary infiltrates or 
progressive decrease in pulmonary function may require medical therapy. Recent 
reviews [5, 54] support the idea of initiating therapy in the case of systemic disease 
with potential of progression to permanent organ damage or life-threatening condi-
tions (such as arrhythmias).
Figure 6. 
MRI in a patient with liver and splenic sarcoidosis demonstrating hypoattenuation of splenic lesions (A). MRI 
in the same patient demonstrating hepatosplenomegaly (B).
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Data for the management of liver sarcoidosis is gathered from small trials and 
case reports. The following recommendations may be followed:
• In patients with asymptomatic liver disease or mildly elevated liver enzymes 
without cholestasis, observation is required. Incidentally discovered hepato-
megaly falls under this category [55].
• In patients with symptomatic liver disease, cholestasis or risk for hepatic 
complications, medical treatment is required.
The first line of treatment includes steroids and ursodeoxycholic acid (UDCA). 
Alternatively, azathioprine, methotrexate, glutathione, cyclosporine, cyclophos-
phamide, thalidomide and infliximab have been studied in the management of liver 
sarcoidosis.
The beneficial effect of corticosteroids is based on their ability to suppress the 
inflammatory response, thus decreasing the number of liver granulomas and the 
liver size, as well as ameliorating constitutional symptoms. Low-dose prednisone 
(10–20 mg/day) is recommended for patients with mild disease, while higher 
doses can be required in patients with severe symptoms. Treatment duration varies 
according to clinical and laboratory response, with up to 1 year of treatment before 
tapering the doses [56]. However, steroids have not proven beneficial for asymp-
tomatic patients or patients with advanced stages of liver disease, including cirrho-
sis and portal hypertension [19].
UDCA has proven effective especially in patients with liver sarcoidosis mani-
fested by pruritus. Recent trials has also proven its effect on delaying disease 
progression. One study has even proved that UDCA is superior to prednisone in 
improving cytolysis syndrome, pruritus and fatigue [57]. The usual daily dose of 
UDCA is 13–15 mg/kg.
Table 2 summarizes case reports with unusual treatment and evolution of liver 
sarcoidosis.
Drug Dosage Time to 
improvement
Remarks Reference
Infliximab 3 mg/kg at 8 weeks 6 weeks A patient with cirrhosis, 
portal hypertension and 
refractory ascites
[58]
Azathioprine 50–150 mg/kg 8 weeks 4 patients [23]
Methotrexate 10–15 mg/week 6 months 2 patients, with 
improvement in liver 
function tests
[59]
Leflunomide 20 mg/day 6 months 1 patient [60]
Cyclosporine 20–200 mg/day Mean treatment 
duration 4 years
9 patients after liver 
transplantation for 
sarcoidosis
[61]
Thalidomide 100–200 mg/kg 7–12 months 3 patients with 
concomitant skin lesions
[62]
Mycophenolate 
mofetil
250 mg/m2 up to 
1 g/m2
1 month 1 patient with pediatric-
onset adult sarcoidosis
[30]
Table 2. 
Treatment options for liver sarcoidosis.
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Nevertheless, it is essential to remember standard treatment measures in 
patients with advanced liver disease [19]. These patients may benefit from liver 
transplantation, with 60% survival at 5 years [63]. Careful monitoring is required 
as reports of sarcoidosis recurrence after transplantation have emerged.
7. Conclusions
Liver sarcoidosis is a frequent involvement in an otherwise rare disease. 
Having an incompletely elucidated etiology, its clinical and biological spectrum is 
extremely vast, and with few reports and no substantial clinical trials, its manage-
ment is mainly patient-based. However, suspicion of systemic sarcoidosis in a 
patient should warrant extensive evaluation for associated liver disease, as this may 
impact the prognosis of the patient in the clinical history. The fact that this condi-
tion can progress to end-stage liver disease and can represent an indication for liver 
transplantation should set sarcoidosis among hepatopathies to be clearly diagnosed 
and monitored.
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